<DOC>
	<DOCNO>NCT00130507</DOCNO>
	<brief_summary>Eligible patient must receive vinorelbine plus capecitabine , without trastuzumab , disease progression unbearable toxicity . Cycles administer every 3 week . HER2 status must locally assess immunohistochemistry ( IHC ) . All 3+ patient eligible . In 2+ patient , HER2 status must confirm fluorescence situ hybridization ( FISH ) . Principal outcome clinical benefit ( complete + partial response + stable disease ) . Sample size arm estimate Fleming method . Previous data show clinical benefit rate vinorelbine plus capecitabine around 50 % . The researcher assume trastuzumab increase 20 % . With alpha error 0.05 80 % power , 37 patient per arm need . This randomised phase II trial . With minimum expected benefit rate 50 % , least 36 patient need choose , 90 % probability right , best treatment arm , provide increase benefit rate least 15 % . Assuming drop-out rate 10 % , total number patient need 82 , 41 per treatment arm . Patients stratify per investigational site , presence visceral metastatic lesion ( liver , lung , pleura , heart , peritoneum , suprarenal gland ) . All patient must receive 2 cycle . If disease progression detect , treatment must continue progression unbearable toxicity .</brief_summary>
	<brief_title>Benefit Adding Trastuzumab Second Line Chemotherapy Breast Cancer Patients Previously Treated With Trastuzumab</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Written inform consent . Women old 18 year old . HER2 positive breast cancer histological diagnosis . Nonoperable locally advanced metastatic disease , previously treat trastuzumab taxanes . Measurable nonmeasurable disease per Response Evaluation Criteria Solid Tumors ( RECIST ) . Disease progression treatment trastuzumab taxanes . Maximum 1 previous chemotherapy line advance metastatic disease . Previous radiotherapy allow radiated area document lesion . At least 4 week since last administration antineoplastic treatment toxicity resolve . Performance status Eastern Cooperative Oncology Group ( ECOG ) &gt; =2 . Life expectancy least 12 week . Left Ventricular Ejection Fraction ( LVEF ) evaluation ( &gt; =50 % ) previous 4 week . Hematology : neutrophil &gt; =1.5 x 10e9/l ; platelet &gt; = 100 x 10e9/l ; hemoglobin &gt; = 10 mg/dl Hepatic function : total bilirubin &lt; = 1.5 xUNL ; SGOT SGPT alkaline phosphatase &lt; = 2.5xUNL , &lt; =5xUNL hepatic lesion present Renal function : creatinine &lt; = 175 Âµmol/l ( 2 mg/dl ) ; creatinine clearance &gt; = 60 ml/min . Patients able comply treatment followup . Negative pregnancy test previous 14 day . Adequate contraceptive method treatment 3 month finalise . Brain metastatic lesion allow provide criterion meet . Male meet inclusion criterion eligible . History hypersensitivity vinorelbine , trastuzumab , rat protein trastuzumab component . History dyspnea rest , chronic oxygen therapy require . Active infection . Second malignancy , except cervical situ carcinoma , basal skin carcinoma , adequately treat . Previous malignancy 5 year disease free survival allow . Pregnant lactating woman . Any serious medical pathology , congestive heart failure , unstable angina , history myocardial infarction previous year , uncontrolled HA high risk arrhythmias . History neurological psychiatric disorder , could preclude patient free informed consent . Active uncontrolled infection . Active peptic ulcer , unstable diabetes mellitus . Concomitant treatment investigational product . Participation clinical trial nonmarketed drug 30 previous day randomization . Concomitant treatment therapy cancer .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>HER2 positive breast cancer .</keyword>
	<keyword>Progression trastuzumab taxanes .</keyword>
</DOC>